Form 4 for TNXP Tonix Pharmaceuticals Holding Corp.
Accepted 2022-07-01 00:00:00 ET · period of report 2022-06-29 · accession 0001387131-22-007441 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-07-01 | 2022-06-29 | TNXP | LEDERMAN SETH | CEO, Dir | P - Purchase | $1.71 | +20.0K | 24.2K | +472% | +$34.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.001 par value | 2022-06-29 | P | A | 20,000 | $1.71 | 24,235 | I By IRA Account | — | — | (F1) Shares reported reflect a 1-for-32 reverse stock split effective May 17, 2022. |